

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

Hamburg, Germany, 06 September 2017:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare Conference 2017 in London, UK.

Goldman Sachs' 7th Annual Biotech Symposium, London, UK

- ▶ **Date:** *Friday, 08 September 2017*
- ▶ **Venue:** *London, UK*
- ▶ **Attendee:** *Enno Spillner, Chief Financial Officer of Evotec AG*

Morgan Stanley 15th Annual Global Healthcare Conference, New York, USA

- ▶ **Date:** *Monday, 11 September 2017, 04.50 pm EDT (09.50 pm BST, 10.50 pm CEST)*
- ▶ **Venue:** *New York, NY, USA*
- ▶ **Attendee:** *Dr Werner Lanthaler, Chief Executive Officer of Evotec AG*

Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK

- ▶ **Date:** *Thursday, 14 September 2017*
- ▶ **Venue:** *London, UK*
- ▶ **Attendee:** *Enno Spillner, Chief Financial Officer of Evotec AG*

**6th German Corporate Conference, Berenberg/Goldman Sachs,
Munich, Germany**

- ▶ **Date:** *Monday, 18 September 2017, 11.00 am CEST (10.00 am BST, 05.00 am EDT)*
- ▶ **Venue:** *Munich, Germany*
- ▶ **Attendee:** *Enno Spillner, Chief Financial Officer of Evotec AG*

Baader Investment Conference, Munich, Germany

- ▶ **Date:** *Wednesday, 20 September 2017, 05.15 pm CEST (04.15 am BST, 11.15 am EDT)*
- ▶ **Venue:** *Munich, Germany*
- ▶ **Attendee:** *Dr Werner Lanthaler, Chief Executive Officer of Evotec AG*

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter [@EvotecAG](https://twitter.com/EvotecAG).

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.